PARP Inhibitors in Prostate Cancer - Recent Updates and Implications for Clinical Practice - Enduring Recorded Webcast

This accredited continuing education activity “PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice,” is recorded from the live webinar held on 10/31/2022. 

If you participated in the live webinar titled - PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice on 10/29/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 10/29/2023.  However, you may enroll in this activity to review the contents. 

The recorded lectures and subsequent discussions feature leading experts in prostate cancer who provide a comprehensive overview of the recent updates and implications of clinical practice.

This CME-accredited activity, PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice, is designed to provide expert interpretation of new and emerging data on the treatment of prostate cancer with PARP inhibitors (PARPi) as a single agent or potential new combination treatments. Expert faculty will discuss the essentials of clinical trial data and current and emerging treatment strategies and place them within a practical and contemporary clinical context for developing and maintaining updated care pathways for patients with advanced prostate cancer. The goal of this activity is to improve knowledge and advance the ability of oncology providers to apply current and emerging treatment strategies with PARPi to the clinical Practice in improving outcomes of patients with prostate cancer.

REGISTRATION FEES:

This activity is free for all

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with advanced prostate cancer
  • Summarize current clinical trial data and clinical applications for new and emerging therapies, including PARP inhibitors combined with androgen receptor-targeted therapies 
  • Review the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with advanced prostate cancer
  • Identify and manage treatment-related toxicities based on recent clinical trials data on PARP inhibitors
  • Review the role of germline and somatic mutation testing and identification of biomarkers that predict PARP inhibitor sensitivity
Course summary
Available credit: 
  • 1.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.75 Contact Hours.
Course opens: 
10/29/2023
Course expires: 
10/29/2024
Cost:
$0.00

This educational activity features recorded videos from the live webinar titled - PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice held 10/29/2023.

The video is placed in the following order

Participants should claim continuing education credits to the extent of their participation.

Rationale for PARPi in the management of prostate cancer - Alexandra Sokolova, MD

Combination of PARP-I + ARSI and other PARPi combinations - Benjamin Garmezy, MD

PARPi in metastatic hormone sensitive prostate cancer and earlier disease settings - Karine Tawagi, MD

Germline and somatic mutation testing and identifying predictive biomarkers for PARPi - Natalie Reizine, MD

Toxicities management of regimens including PARPi - Jason Brown, MD, PhD

Panel discussion -  Benjamin Garmezy, MD,  Karine Tawagi, MD, Natalie Reizine, MD, and Jason Brown, MD, PhD

 

Jason Brown 

has a financial relationship (Other) with AstraZeneca; financial relationship (Other) with EMD Serono.

Benjamin Garmezy, MD 

has a financial relationship (Other) with Nuvation Bio; financial relationship (Other) with Zenshine; financial relationship (Other) with Merck; financial relationship (Other) with Accutar; financial relationship (Other) with CRISPR Therapeutics; financial relationship (Other) with IDEAYA Biosciences; financial relationship (Other) with Kineta; financial relationship (Other) with Mink Therapeutics; financial relationship (Other) with Xencor; financial relationship (Other) with Bayer; financial relationship (Other) with SeaGen; financial relationship (Other) with Abbvie; financial relationship (Other) with AVEO; financial relationship (Other) with Harbour BioMed; financial relationship (Other) with Jubilant Therapeutics; financial relationship (Other) with TEON Therapeutics; financial relationship (Other) with Arvinas; financial relationship (Other) with Sanofi-Aventis; financial relationship (Other) with AstraZeneca; financial relationship (Other) with Genetech/Roche; financial relationship (Other) with Janux Therapeutics; financial relationship (Other) with Loxo; financial relationship (Other) with Profound Bio; financial relationship (Other) with Amgen ; financial relationship (Other) with Pfizer; financial relationship (Other) with Arcus; financial relationship (Other) with Exelixis; financial relationship (Other) with Janssen; financial relationship (Other) with Kinnate Biopharma.

Natalie Reizine, MD

has a financial relationship (Financial Support) with EMD Serono; financial relationship (Financial Support) with Sanofi; financial relationship (Financial Support) with Tempus; financial relationship (Financial Support) with AstraZeneca; financial relationship (Financial Support) with Janssen; financial relationship (Financial Support) with Merck; financial relationship (Financial Support) with Exelexis.

Alexandra Sokolova 

has a financial relationship (Professional Services) with Lantheus; financial relationship (Travel) with Asta Zeneca.

Karine Tawagi 

has no relevant financial relationships to disclose at this time.

 

Important Information about Claiming CME for this activity:

If you participated in the live webinar titled - PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice on 10/29/2023 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 10/29/2023. However, you can still enroll in this activity and review the contents as needed.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported with an independent medical education grant from the following companies:

  • Merck Sharp & Dohme LLC
  • AstraZeneca Pharmaceuticals

Available Credit

  • 1.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.75 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.